Efficacy of Antiretroviral Therapy in Individuals Infected With HIV-1 Non-B Subtypes
África Holguín 1, Eva Ramírez de Arellano 1, Pablo Rivas 1, Vicente Soriano 2
1 NULL; 2 UNIR Health Sciences School and Medical Center, Universidad Internacional de La Rioja, Madrid, Spain
*Correspondence: África Holguín, Email not available
Abstract
The impact of HIV-1 subtype on clinical outcome following exposure to antiretroviral therapy is currentlynot well known. Natural polymorphisms are often present in HIV-1 non-B subtypes at positions known tobe associated with drug resistance in clade B viruses. These changes might influence the emergence ofdrug-resistant viruses, modifying drug susceptibility and/or the virus replicative capacity. Moreover, differentpathways may lead to drug resistance according to HIV-1 clade. Finally, the influence of subtypeon the performance of phenotypic assays and in the interpretation of algorithms for genotypic resistanceis currently a matter of debate. All these aspects explain why the response to antiretroviral therapy mightvary in subjects infected with different HIV-1 clades.
